Patient-oriented research has clearly shown that the risk of getting another disease increases when the patient already has a disease. This has been demonstrated not least by Swedish registry research. Since the sequencing of the human genome in 2000, a very large number of genetic studies have been carried out and today we know that over 1000 different genetic DNA variants in the genome can be associated with various common diseases. An interesting finding in these studies is that several diseases share genetic variants, which suggests that different diseases may have similar biological mechanisms where especially immune-related genes recur. In the last 5-10 years, there has been an explosive development in translational cellular immunology where the adaptive immune system controls the development of diseases such as MS, RA, CVD, psoriasis, various cancers and gastrointestinal diseases. Several phase III studies are therefore underway where drugs that attack specific cellular mechanisms of these so-called TH17 and Treg cells in the adaptive immune system. There are also drugs on the market today that affect these cells' production of various inflammation-inducing cytokinins. In our project, we intend to experimentally map key signaling pathways in humans in these two cell types using new powerful genomic techniques closely linked to bioinformatic analysis. The clinical relevance is that we will be able to identify new selective mechanisms that intervene in the inflammation and also find new biomarkers.